Joint Pain Injections Market By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections, Others), By Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.
According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.
Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.
Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U.S. However, the government of Australia has published ‘The National Strategic Action Plan for Arthritis’ that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.
In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U.S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.
However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.
The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Injection Type
Interleukin Inhibitors
Hyaluronic Acid Injections
Others
By Joint Type
Knee and Ankle
Hip Joint
Shoulder and Elbow
Facet Joints of the Spine
Others
By Distribution Channel
Hospital Pharmacies
Type
Public Hospital Pharmacies
Private Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbvie Inc
Anika Therapeutics
Bioventus
Eli Lilly and Company
Ferring Pharmaceuticals Inc.
PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceuticals
Zimmer Biomet
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook